illuminaDx™

Introduction to Illumina Diagnostics

Emily Winn-Deen, PhD
Vice President, Product Development
Diagnostics

© 2010 Illumina, Inc. All rights reserved.
Illumina, illumina*Dx*, Solexa, Making Sense Out of Life, Oligator, Sentrix, GoldenGate, GoldenGate Indexing, DASL, BeadArray, Array of Arrays, Infinium, BeadXpress, VeraCode, IntelliHyb, iSelect, CSPro, GenomeStudio, Genetic Energy, and HiSeq are registered trademarks or trademarks of Illumina, Inc. All other brands and names contained herein are the property of their respective owners.

Corporate Overview

- Founded in 1998
- Initial Public Offering on July 27, 2000
- Headquarters in San Diego, CA
- More than 500,000 square ft. of facility space in 6 countries
- Over 1,800 employees
- IP portfolio of 135 issued patents and 168 pending applications
- Ranked #1 on Forbes' list of Fastest Growing Technology Companies in 2009 & 2007
- Added to the NASDAQ-100 listing in 2008

illuminaDx™

A Global Organization

Expanded Manufacturing, R&D, Sales, Service & Support

Over 1800 Employees
>150 Sales Personnel
>300 Customer Solutions Personnel

illuminaDx™

Markets Served



illuminaDx™

Growth Opportunities for Genetic Analysis

Total Addressable Market

Today: ~$6.6B



2011: ~$10.1B



Market estimates in $billions

illuminaDx™

Industry Leading Growth

Strong Performance While Reinvesting in New Opportunities

53% Revenue CAGR



Non-GAAP Operating Profit and Earnings per Share

illuminaDx™

Integrated Solutions

That Advance the Understanding of Genetics and Health

HiSeq 2000

iScan

BeadXpress





Whole Genome, Regulatory & Targeted Sequencing

Whole Genome, Targeted & Custom Microarrays

Low Complexity Targeted, Custom Arrays

illuminaDx™

Supporting Rich & Divergent Applications



illuminaDx™

Resources to Provide Complete Solutions



illuminaDx™

Illumina's Matrixed Organization



illuminaDx™

IlluminaDx Vision

- Our vision is to become a leader in translational medicine, focusing on complex diseases that benefit from high performance analysis, including genotyping, copy number, gene expression, methylation and protein analysis.
- We leverage the strength of our technologies in four major areas:

Molecular Diagnostics

Molecular Cytogenetics

Clinical Services

Oncology Discovery

IlluminaDx™ Seminar Series

The Next Generation of Molecular Diagnostic Tests, Systems, and Services

Seminar Schedule		
9:00	Registration	
9:30	Introduction to IlluminaDx	Emily Winn-Dean, VP of Product Development of Diagnostics, Illumina
9:45	Maximizing the Multiplexing Capabilities of the BeadXpress System	Gianluca Roma, Illumina
10:00	Pharmacogenetics Research Standardized : The ADME Core List and VeraCode ADME Core Panel	Michael Phillips, PhD Montreal Heart Institute Pharmacogenomics Centre
10:30	Identifying Chromosomal Abnormalities Using Infinium SNP BeadChips	Harper VanSteenhouse, PhD, Illumina and Michael Phillips, PhD Montreal Heart Institute Pharmacogenomics Centre
11:15	Clinical Genome Sequencing Service	Julianne O'Daniel, CGC, Illumina
12:00	Lunch	Café
1:00	A Platform Approach to Translational Cancer Discovery and Diagnostic Development	Naomi O'Grady, Illumina
1:45	Conclusion	

illuminaDx™